非酒精性脂肪性肝病发病机制及治疗进展

非酒精性脂肪性肝病(NAFLD)是代谢综合征在肝脏的组成部分,是全球范围内广泛流行的慢性肝病。胰岛素抵抗(IR)可引起肝脏糖脂代谢紊乱,导致脂肪变。脂肪因子和炎性因子相互作用可导致IR,引起脂肪肝炎性改变,使NAFLD患者进展为非酒精性脂肪性肝炎(NASH)、肝纤维化甚至肝细胞癌。鉴于此,胰岛素增敏剂二甲双胍及噻唑烷二酮类药物能有效地治疗NAFLD。该文就NAFLD的发病机制与胰岛素增敏剂抗病机制及疗效予以综述。

Progress on the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Diseas

Non-alcoholic fatty liver disease （NAFLD）, which is a part of the metabolic syndrome in the liver,is a prevalent chronic liver disease worldwide. Insulin resistance（IR） causes liver lipid metabolism disturbance,leading to hepatic steatosis. The interaction between adipokines and cytokines can lead to insulin resistance（IR） , and cause inflammatory changes of fatty liver at the same time, in which could make NAFLD patients progress to non-alcoholic steatohepatitis （NASH）, liver fibrosis or hepatocellular carcinoma. Insulin resistance plays an important role in the pathogenesis of NAFLD. Insulin sensitizers （ mefformin and thiazo- lidinedione） can improve insulin resistance and regulate adipokines and cytokines in patients of NAFLD. Here is to make a review of the pathogenesis of NAFLD and resistant mechanism of insulin sensitizers and their efficacy in treating NAFLD.